LCDActive
Select Minimally Invasive GERD Procedures
L35080
National Government Services, Inc. (J06)
Effective: February 10, 2022
Updated: December 31, 2025
Policy Summary
Transoral incisionless fundoplication (TIF) using the EsophyX device is covered for treatment of GERD when the gastroesophageal valve is reconstructed and any hiatal hernia is ≤2 cm (or has been reduced to ≤2 cm by prior laparoscopic repair). Multiple specific exclusions apply: TIF is not covered for patients with BMI >35, LA grade esophagitis >B, Barrett's >2 cm, achalasia, esophageal ulcer, lack of an appropriate PPI trial, or prior failed TIF (repeat TIF is investigational); other endoluminal procedures and LINX are non-covered and will be denied as not proven effective.
Coverage Criteria Preview
Key requirements from the full policy
"Transoral incisionless fundoplication (TIF) using the EsophyX device for treatment of gastroesophageal reflux disease (GERD) is covered to reconstruct the gastroesophageal valve and reduce acid ref..."
Sign up to see full coverage criteria, indications, and limitations.